Development of porous silicon nanocarriers for parenteral peptide delivery.
暂无分享,去创建一个
K. Järvinen | K. Herzig | J. Salonen | V. Lehto | J. Mönkäre | M. Kovalainen | Martti Kaasalainen | J. Riikonen
[1] A. Jalanko,et al. Native and Complexed IGF-1: Biodistribution and Pharmacokinetics in Infantile Neuronal Ceroid Lipofuscinosis , 2012, Journal of drug delivery.
[2] Mesoporous Silicon (PSi) for Sustained Peptide Delivery: Effect of PSi Microparticle Surface Chemistry on Peptide YY3-36 Release , 2012, Pharmaceutical Research.
[3] C. Prestidge,et al. Surface chemical modification to control molecular interactions with porous silicon. , 2011, Journal of colloid and interface science.
[4] A. Seifalian,et al. Current trends in the application of nanoparticles in drug delivery. , 2011, Current medicinal chemistry.
[5] K. Järvinen,et al. Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[6] M. Ferrari,et al. In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. , 2010, International journal of pharmaceutics.
[7] Vesa-Pekka Lehto,et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. , 2010, ACS nano.
[8] M Ferrari,et al. Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[9] M. Khrestchatisky,et al. Synthetic therapeutic peptides: science and market. , 2010, Drug discovery today.
[10] Vesa-Pekka Lehto,et al. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[11] R. Batterham,et al. The role of peptide YY in appetite regulation and obesity , 2009, The Journal of physiology.
[12] C. Beglinger,et al. Pharmacokinetics and Pharmacodynamic Effects of Oral GLP‐1 and PYY3‐36: A Proof‐of‐concept Study in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.
[13] L. Karhunen,et al. Effect of protein, fat, carbohydrate and fibre on gastrointestinal peptide release in humans , 2008, Regulatory Peptides.
[14] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[15] Mauro Ferrari,et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.
[16] J. Salonen,et al. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles. , 2007, International journal of pharmaceutics.
[17] A. Astrup,et al. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. , 2007, American journal of physiology. Endocrinology and metabolism.
[18] S. Heymsfield,et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. , 2007, The Journal of clinical endocrinology and metabolism.
[19] R. Pandey,et al. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. , 2004, The Journal of antimicrobial chemotherapy.
[20] Rabah Boukherroub,et al. Thermal Hydrosilylation of Undecylenic Acid with Porous Silicon , 2002 .
[21] V. Mutt,et al. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides , 1980, Nature.